MainBanner
PerioTrap is a clinical stage Biotech company that aims to eradicate the root cause of periodontitis
Background

Periodontitis is an inflammation of the gums mainly caused by a microbiotic shift towards pathogenic bacteria.

Periodontitis is an inflammation of the gums mainly caused by a microbiotic shift towards pathogenic bacteria.

Periodontitis is an inflammation of the gums mainly caused by a microbiotic shift towards pathogenic bacteria. As a chronic disease it requires constant management.

It affects nearly 20 - 50% of the global population and is associated with a range of co-morbitities like diabetes or Alzheimer’s disease.

It affects nearly 20 - 50% of the global population and is associated with a range of co-morbitities like diabetes or Alzheimer’s disease.

It affects nearly 20 - 50% of the global population and is associated with a range of co-morbitities like diabetes or Alzheimer’s disease.

Current treatments involve painful removal of the whole biofilm followed by daily disinfection or antibiotics that keep disrupting the natural biofilm. Therefore patients loose biofilm homeostasis incl. beneficial bacteria with its metabolic and immunologic support and are more prone to recurrent infections.

Current treatments involve painful removal of the whole biofilm followed by daily disinfection or antibiotics that keep disrupting the natural biofilm. Therefore patients loose biofilm homeostasis incl. beneficial bacteria with its metabolic and immunologic support and are more prone to recurrent infections.

Current treatments involve painful bacteria removal and daily disinfection, disrupting microbiome balance and impairing beneficial bacteria's metabolic and immunologic functions.

Approach
We‘ve developed an innovative anti-infective drug that is capable of targeting only the disease causing pathogens and therefore represents an effective alternative to classic broad spectrum antibiotics. Protecting the commensal bacteria should encourage a shift towards a natural microbiome, thus preventing the reoccurrence of the disease.
The key element of this strategy is an enzyme called glutaminyl cyclase (QC) type II, which is exclusively present within pathogenic bacteria of the oral biofilm where Porphyromonas gingivalis is the main catalyst of the disease.
Team
Team

PerioTrap possesses many years of experience in drug development. The company’s team combines competences in the field of medicinal chemistry, compound characterization, microbiology, clinical and product development.

The collective track record includes the successful development of several drug development projects in the area of small molecules. This includes the development of DP4 inhibitors as antidiabetics and the development of a novel pharmacological approach for the treatment of Alzheimer's disease (currently in phase IIb).

Team members
Dr. Mirko Buchholz
CSO
Mirko is the CSO of PerioTrap Pharmaceuticals with 20 years of experience in drug development. He is a pharmacist by training and holds a PhD in Medicinal-/Computational Chemistry. Previously he worked at Probiodrug AG (now Vivoryon AG) for more than 10 years on several positions, before he was a group leader for medicinal and analytical chemistry at Fraunhofer IZI-MWT. He is one of the co-founder of the company as a spin-off from the institute.
Pierre Tangermann
CEO
Pierre holds the CEO position of PerioTrap Pharmaceuticals GmbH. Previously, he has served as business development manager at the Fraunhofer-Institute for Cell Therapy and Immunology in Leipzig and was later heading the business development and marketing department of its subsidiary in Potsdam. He graduated in Biochemistry (M.Sc.) at Leipzig University and the University of Queensland as well as in General Management (M.A.) at the University of Applied Sciences Leipzig.
Dr. Nadine Taudte
Senior Scientist
Our Senior Scientist Nadine holds a diploma in Biology and a PhD in Molecular Microbiology from MLU Halle/ Wittenberg with residences at the University of Arizona and Nebraska-Lincoln. After working several years in drug development for a BioTech Company and Fraunhofer in the field of target validation, Nadine now closes the gap to her microbiological roots supervising our pathogenic work and drug testing.
Team members Reihe 2
Anett Theisen
Clinical Manager
Anett is a highly skilled professional with a Diploma in Biology from the University of Bayreuth. Boasting 17 years of invaluable experience in the execution of clinical trials and the development of quality management systems, Anett has demonstrated a consistent commitment to excellence. Her expertise in Good Clinical Practice (GCP) and vendor auditing will seamlessly integrate these roles into the overarching quality management framework. Her proficiency ensures meticulous compliance and upholds the highest standards in the execution of clinical trials.
Grit Rehbein
Product Developer
Grit currently works in Project Management, Product Development, and Quality Management. With 20 years of comprehensive experience in Research and Development (R&D) and scientific management within the biomedical research sector, including a PhD and PostDoc at Uniklinik Halle, the medical faculty of MLU, she brings a seasoned perspective and proven expertise to her current roles at PerioTrap. In the last 8 years, Grit has developed products and ensured Quality Management in line with ISO 13485 standards. Her accomplishments include setting up small-series production and contributing to planning a fully automated production line for In Vitro Diagnostics (IVDs).
Advisory Board
Advisory Board
Prof. Dr. Hans-Ulrich Demuth

Honorary Professor of Proteinbiotechnolgy, Department of Biotechnology, Anhalt University of Applied Science, Köthen, Germany

Read more
Prof. Dr. Sigrun Eick

School of Dental Medicine, University of Bern

Read more
Prof. Dr. Jan Potempa

Head of Microbiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland and Distinguish University Scholar, Department of Oral Immunity and Infectious Diseases, University of Louisville School of Dentistry, Louisville, KY, USA.

Read more
Prof. Dr. Dr. h.c. Holger Jentsch

Clinic for Cariology, Endodontology and Periodontology, University Hospital of Leipzig.

Read more
Dr. Özlem Weiss

IBD Consulting & Co.

Read more
Prof. Dr. Karsten Mäder

Pharmaceutical Technology, Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Halle, Germany

Read more